Home  /  Resource Library  /  Outcomes related to FDG-PET-CT response in patients with Hodgkin Lymphoma treated with brentuximab vedotin at relapse or consolidation

Outcomes related to FDG-PET-CT response in patients with Hodgkin Lymphoma treated with brentuximab vedotin at relapse or consolidation

Results of a study investigating pet scan directed therapy with Brentuximab Vedotin for treatment of relapsed Hodgkin lymphoma. (Abstract only)